Form 4: Travere CMO Reports Equity Activity and Tax-Related Sale

Travere Therapeutics' Chief Medical Officer, Jula Inrig, reported the acquisition of restricted stock units and stock options, alongside a tax-related sale of common stock.

Summary

• Jula Inrig, Chief Medical Officer of Travere Therapeutics, Inc. (TVTX), reported changes in beneficial ownership.
• On January 31, 2026, 28,130 shares of Common Stock were acquired through restricted stock units (RSUs) at a price of $0, increasing direct beneficial ownership to 114,441 shares.
• Also on January 31, 2026, 75,000 employee stock options were acquired with an exercise price of $33.095 per share, vesting over time and expiring on January 31, 2036.
• On February 3, 2026, 6,956 shares of Common Stock were disposed of at a price of $32.12 per share.
• This disposition was a 'sell to cover' transaction to satisfy tax withholding obligations related to the settlement of vested restricted stock units and was not a discretionary trade.
• Following these transactions, direct beneficial ownership of Common Stock stands at 107,485 shares, and 75,000 employee stock options are beneficially owned.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive. The acquisition of significant equity awards (RSUs and options) by a key executive is generally positive, aligning interests. The subsequent sale was non-discretionary and for tax purposes, which is a routine event and does not reflect a negative sentiment from the insider.

Positives

• The Chief Medical Officer received a significant grant of 28,130 restricted stock units and 75,000 employee stock options, aligning her interests with shareholders.
• The disposition of shares was explicitly stated as a non-discretionary 'sell to cover' transaction for tax withholding, indicating no voluntary sale by the insider.

Negatives

• A total of 6,956 shares of Common Stock were sold, reducing the Chief Medical Officer's direct beneficial ownership by that amount.

Future Outlook

The employee stock options granted on January 31, 2026, will vest over time, with one-fourth becoming exercisable on the first anniversary of the grant date, and the remaining shares vesting in 36 equal monthly installments thereafter. The restricted stock units represent a contingent right to receive shares in the future.

Management Comments

• The sale of 6,956 shares was mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a 'sell to cover' transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures of insider transactions, providing transparency into executive and director equity holdings. The 'sell to cover' transaction is a common mechanism for insiders to meet tax obligations upon the vesting of equity awards, and typically does not signal a change in management's outlook on the company's prospects.

Stakeholder Impact

• Shareholders: The Chief Medical Officer's increased equity holdings (RSUs and options) align her long-term interests with those of shareholders, potentially fostering greater commitment to company performance. The tax-related sale is a routine event and unlikely to have a significant impact.

Next Steps

• The employee stock options will begin vesting one year from the grant date (January 31, 2026), with subsequent monthly vesting installments.

Key Dates

Keywords

Travere Therapeutics, TVTX, Jula Inrig, Chief Medical Officer, Form 4, Insider Trading, Restricted Stock Units, Stock Options, Equity Compensation, Beneficial Ownership